Cargando…

Response of prostate cancer to addition of dutasteride after progression on abiraterone

Detalles Bibliográficos
Autores principales:	Lian, Jian-Po, Gao, Yuan-Yuan, Tang, Jing-Jie, Chen, Xi, Liu, Ying, Wu, Deng-Long, Li, Zhen-Fei, Huang, Sheng-Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991817/ https://www.ncbi.nlm.nih.gov/pubmed/32896838 http://dx.doi.org/10.4103/aja.aja_45_20

Ejemplares similares

Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia
por: Saceda-Corralo, David, et al.
Publicado: (2017)

The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients
por: Liu, Ying, et al.
Publicado: (2022)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Bone Health Risks Associated with Finasteride and Dutasteride Long-Term Use
por: Sirufo, Maria Maddalena, et al.
Publicado: (2021)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
por: Rajvanshi, Jignesh B., et al.
Publicado: (2019)

Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate
por: Wang, Jiang-Yi, et al.
Publicado: (2022)

Comment on ‘Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
por: Shamash, J, et al.
Publicado: (2014)

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
por: Omlin, A, et al.
Publicado: (2014)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007)

Characteristics of prostate biopsy in patients under the dutasteride treatment
por: Obinata, Daisuke, et al.
Publicado: (2022)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
por: Miller, J, et al.
Publicado: (2009)

The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride
por: Choi, Yong Hyeuk, et al.
Publicado: (2010)

The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus
por: Daryanto, Besut, et al.
Publicado: (2023)

Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro
por: Kuzmanov, Aleksandar, et al.
Publicado: (2023)

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia
por: Ragi, Sara D., et al.
Publicado: (2023)

Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures
por: Kim, Min-Soo
Publicado: (2013)

The Effect of Two Weeks of Treatment with Dutasteride on Bleeding after Transurethral Resection of the Prostate
por: Kim, Kyu Shik, et al.
Publicado: (2015)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
por: Sundar, Santhanam, et al.
Publicado: (2015)

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
por: Li, Yao, et al.
Publicado: (2022)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
por: Thomson, Andrew
Publicado: (2005)

Preparation, Characterization and Stability Study of Dutasteride Loaded Nanoemulsion for Treatment of Benign Prostatic Hypertrophy
por: Ali, Mohammad Sajid, et al.
Publicado: (2014)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2–10 ng/mL at initial biopsy
por: He, Ya-Di, et al.
Publicado: (2021)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
por: Shanmugasundaram, R., et al.
Publicado: (2007)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

LINCS Dataset-Based Repositioning of Dutasteride as an Anti-Neuroinflammation Agent
por: Luo, Dan, et al.
Publicado: (2021)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
por: Tani, Masaru, et al.
Publicado: (2023)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2013)

Cerebral Venous Sinus Thrombosis Associated with Dutasteride Use
por: Choi, Bo Kyu, et al.
Publicado: (2020)

Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis?
por: Proaño, Belén, et al.
Publicado: (2022)

The Effect of Finasteride and Dutasteride on the Growth of WPE1-NA22 Prostate Cancer Xenografts in Nude Mice
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2012)

Abiraterone Acetate
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_igpcpti1qr4v7ife7t93dfkasq